Cost-effectiveness of durvalumab with or without olaparib as a first-line treatment for dMMR type of advanced/recurrent endometrial cancer.

IF 1.5 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-08-20 DOI:10.1080/14737167.2025.2550426

Jerusha Daggolu, Javeria Khalid, Hua Chen, Moosa Tatar

{"title":"Cost-effectiveness of durvalumab with or without olaparib as a first-line treatment for dMMR type of advanced/recurrent endometrial cancer.","authors":"Jerusha Daggolu, Javeria Khalid, Hua Chen, Moosa Tatar","doi":"10.1080/14737167.2025.2550426","DOIUrl":null,"url":null,"abstract":"Background: In the phase III DUO-E trial, durvalumab with or without olaparib significantly increased survival outcomes compared to chemotherapy alone among patients with endometrial cancer. The aim of this study was to assess the cost-effectiveness of durvalumab in patients with advanced/recurrent dMMR endometrial cancer.Research design and methods: A Markov model was used to compare the cost-effectiveness of durvalumab with or without olaparib compared to chemotherapy alone in the treatment of advanced/recurrent dMMR endometrial cancer, using the data from phase III DUO-E trial. The outcomes evaluated were total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER). One-way sensitivity and probabilistic sensitivity analyses were performed to account for uncertainty.Results: The base case analysis found that durvalumab and chemotherapy had an ICER of $239,884/QALY, whereas durvalumab with olaparib and chemotherapy had an ICER of $259,651/QALY compared to chemotherapy alone. The model was most sensitive to the cost of durvalumab. Probabilistic sensitivity analysis revealed that durvalumab had a 0% likelihood of being considered cost effective at a WTP threshold of $150,000 per QALY.Conclusions: Durvalumab was not cost-effective as a first-line treatment of patients with advanced/recurrent dMMR subtype of endometrial cancer. Reducing the cost of durvalumab might improve economic outcomes.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2550426","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In the phase III DUO-E trial, durvalumab with or without olaparib significantly increased survival outcomes compared to chemotherapy alone among patients with endometrial cancer. The aim of this study was to assess the cost-effectiveness of durvalumab in patients with advanced/recurrent dMMR endometrial cancer.

Research design and methods: A Markov model was used to compare the cost-effectiveness of durvalumab with or without olaparib compared to chemotherapy alone in the treatment of advanced/recurrent dMMR endometrial cancer, using the data from phase III DUO-E trial. The outcomes evaluated were total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER). One-way sensitivity and probabilistic sensitivity analyses were performed to account for uncertainty.

Results: The base case analysis found that durvalumab and chemotherapy had an ICER of $239,884/QALY, whereas durvalumab with olaparib and chemotherapy had an ICER of $259,651/QALY compared to chemotherapy alone. The model was most sensitive to the cost of durvalumab. Probabilistic sensitivity analysis revealed that durvalumab had a 0% likelihood of being considered cost effective at a WTP threshold of $150,000 per QALY.

Conclusions: Durvalumab was not cost-effective as a first-line treatment of patients with advanced/recurrent dMMR subtype of endometrial cancer. Reducing the cost of durvalumab might improve economic outcomes.

查看原文本刊更多论文

durvalumab联合或不联合奥拉帕尼作为dMMR型晚期/复发性子宫内膜癌一线治疗的成本效益

背景：在III期DUO-E试验中，与单独化疗相比，durvalumab联合或不联合奥拉帕尼可显著提高子宫内膜癌患者的生存结果。本研究的目的是评估durvalumab在晚期/复发dMMR子宫内膜癌患者中的成本效益。研究设计和方法：采用Markov模型比较durvalumab联合或不联合奥拉帕尼与单独化疗治疗晚期/复发性dMMR子宫内膜癌的成本-效果，使用来自III期DUO-E试验的数据。评估的结果包括总成本、质量调整生命年（QALYs）和增量成本-效果比（ICER）。进行了单向敏感性和概率敏感性分析以解释不确定性。结果：基本病例分析发现，durvalumab和化疗的ICER为239,884美元/QALY，而durvalumab与奥拉帕尼和化疗相比，单独化疗的ICER为259,651美元/QALY。该模型对durvalumab的成本最为敏感。概率敏感性分析显示，在每个QALY的WTP阈值为150,000美元时，durvalumab被认为具有成本效益的可能性为0%。结论：Durvalumab作为晚期/复发性dMMR亚型子宫内膜癌患者的一线治疗不具有成本效益。降低durvalumab的成本可能会改善经济结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.